High-speed imaging of drops and bubbles

ST Thoroddsen, TG Etoh, K Takehara - Annu. Rev. Fluid Mech., 2008 - annualreviews.org
… 2006a, Gilet et al. 2007, Thoroddsen & Takehara 2000) show that inviscid behavior persists
at … TG Etoh and K. Takehara have a long-standing and ongoing collaboration with Shimadzu …

The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a …

…, PD Sampaio-Barros, P Nash, K Takehara… - Annals of the …, 2009 - ard.bmj.com
Early diagnosis of systemic sclerosis (SSc) may allow the start of treatment that could slow
disease progression. For this reason early diagnosis of the disease is of pivotal importance. …

Skin disease: a cardinal feature of systemic sclerosis

T Krieg, K Takehara - Rheumatology, 2006 - academic.oup.com
Despite the heterogeneity of SSc, almost all patients have skin involvement. As such, skin
manifestations are critical in the initial diagnosis of SSc and in the subsequent sub-…

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind …

…, M Gropp-Meier, T Saito, K Takehara… - The lancet …, 2017 - thelancet.com
Background Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown
efficacy in a phase 2 study when given in capsule formulation to all-comer patients with …

[PDF][PDF] Functional SARS-CoV-2-specific immune memory persists after mild COVID-19

…, PA Morawski, CD Thouvenel, KK Takehara… - Cell, 2021 - cell.com
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is causing a
global pandemic, and cases continue to rise. Most infected individuals experience mildly …

EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)

…, J Seibold, RM Silver, K Takehara… - Annals of the …, 2009 - ard.bmj.com
Purpose: The optimal treatment of systemic sclerosis (SSc) is a challenge because the
pathogenesis of SSc is unclear and it is an uncommon and clinically heterogeneous disease …

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

…, O Ishikawa, H Takahashi, K Takehara… - The Lancet …, 2020 - thelancet.com
Background A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in systemic
sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial lung …

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis …

…, M Gropp-Meier, T Saito, K Takehara… - The Lancet …, 2021 - thelancet.com
Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously
been shown to extend progression-free survival versus placebo when given to patients with …

Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders

…, H Ihn, M Fujimoto, GR Grotendorst, K Takehara - Journal of Investigative …, 1996 - Elsevier
Connective tissue growth factor (CTGF) is a novel peptide that exhibits platelet-derived growth
factor-like activities and is produced by skin fibroblasts after activation with transforming …

Role and interaction of connective tissue growth factor with transforming growth factor‐β in persistent fibrosis: A mouse fibrosis model

…, M Takigawa, T Nakanishi, K Takehara - Journal of cellular …, 1999 - Wiley Online Library
… Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Manabu F, Grotendorst GR, Takehara K.
1996. Connective tissue growth factor gene expression in tissue sections from localized …